PD-1-IN-17 is a small molecule inhibitor that selectively targets the PD-1 receptor, primarily used as a research tool in the field of immunotherapy and cancer biology. It disrupts the PD-1/PD-L1 interaction, thereby enhancing T-cell activation and immune response against tumor cells in preclinical studies. This compound is valuable for investigating checkpoint inhibition mechanisms and developing novel immunotherapeutic strategies. It is not approved for clinical use in humans and is intended solely for laboratory research purposes, such as in vitro assays, animal models, and mechanistic studies related to cancers like melanoma and lung cancer. Research applications may include combination studies with other immunomodulators or chemotherapeutics to explore synergistic effects.